Loading patent…
AssigneeEisai R&D Management Co., Ltd.
InventorsDavid Cox, Alton Kremer, Sharon McGonigle, Jiayi Wu
Estimating the term…
The invention features methods for treating cancer in a patient in need thereof by administering eribulin, in combination with one or more PARP inhibitors, and, optionally, a platinum-based antineoplastic drug, and kits therefor. The invention is based in part on the observation that combinations of eribulin mesylate, a PARP inhibitor (e.g., E7449), and, optionally, a platinum-based antineo-plastic drug (e.g., carboplatin), show improved (e.g., synergistic) antitumor effects. Therefore, the present invention features methods of preventing and treating cancer (e.g., homologous recombination (HR)-deficient cancer by the use of combinations of eribulin (e.g., eribulin mesylate) and one or more PARP inhibitors (e.g., E7449 or a pharmaceutically acceptable salt thereof (e.g., the tartrate salt), optionally in combination with a platinum-based antineoplastic drug (e.g., carboplatin).
A method for treating a subject having or at risk of developing breast cancer, the method comprising administering to the subject (i) eribulin or a pharmaceutically acceptable salt thereof, and (ii) a poly (ADP-ribose) polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt, hydrate, solvate, or amorphous solid thereof.
A method for decreasing the size of a breast cancer tumor in a subject, the method comprising administering to the subject (i) eribulin or a pharmaceutically acceptable salt thereof, and (ii) a PARP inhibitor or a pharmaceutically acceptable salt, hydrate, solvate, or amorphous solid thereof.
Dependencies are inferred from the claim text.